SCHEMBL25022660

SCHEMBL25022660

Cn1cc(-c2ccccc2CN)cn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 2/20 0.52
▸ SMARCA2 P51531 1/20 0.49
▸ SMARCA4 P51532 1/20 0.49
▸ BRD4 O60885 1/20 0.49
▸ ADRA1A P35348 2/20 0.44
▸ PDK2 Q15119 2/20 0.44
▸ ALOX5AP P20292 1/20 0.43
▸ FEN1 P39748 1/20 0.43
▸ PRMT5 O14744 2/20 0.43
▸ WDR77 Q9BQA1 2/20 0.43
▸ GRM2 Q14416 1/20 0.43
▸ LOXL2 Q9Y4K0 1/20 0.43
▸ LCK P06239 1/20 0.42
▸ BTK Q06187 1/20 0.42
▸ ADRA2A P08913 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ CHRM3 P20309 1/20 0.42
▸ METAP2 P50579 1/20 0.42
▸ CSF1R P07333 1/20 0.41
▸ LRRK2 Q5S007 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20777560 0.87 SMARCA2 (0.47) SMARCA2SMARCA4BRD4ADRA1APDK2
SCHEMBL31048702 0.85 BRD4 (0.54) SMARCA2SMARCA4BRD4ADRA1APDK2
SCHEMBL31181988 0.82 BRD4 (0.48) SMARCA2SMARCA4BRD4ADRA1APDK2
SCHEMBL20773248 0.80 CFD (0.52) SMARCA2SMARCA4BRD4ADRA1APDK2
SCHEMBL30332122 0.80 PDK2 (0.48) DPP4BRD4PDK2
SCHEMBL30332368 0.80 DPP4 (0.51) DPP4PDK2FEN1PRMT5WDR77
SCHEMBL23753803 0.78 ALK (0.46) SMARCA2SMARCA4ALOX5APFEN1PRMT5
SCHEMBL14863737 0.78 SMARCA2 (0.45) SMARCA2SMARCA4BRD4ADRA1APDK2
SCHEMBL10544187 0.77 SMARCA2 (0.60) SMARCA2SMARCA4BRD4ADRA1APDK2
SCHEMBL23638914 0.75 BRD4 (0.54) SMARCA2SMARCA4BRD4ADRA1APDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662204-A2 TELOMERASE INHIBITOR COMPOUNDS Geron Corporation (US) 2025-12-17 — — EP disclosed
US-20240352016-A1 A CYCLIN-DEPENDENT KINASE INHIBITOR TAIZHOU EOC PHARMA CO., LTD (CN) 2024-10-24 — — US disclosed
US-20240343713-A1 TELOMERASE INHIBITOR COMPOUNDS BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) 2024-10-17 — — US disclosed
WO-2024168165-A2 TELOMERASE INHIBITOR COMPOUNDS GERON CORPORATION (US) 2024-08-15 — — WO disclosed
EP-4380930-A1 A CYCLIN-DEPENDENT KINASE INHIBITOR Taizhou Eoc Pharma Co., Ltd. (CN) 2024-06-12 — — EP disclosed
WO-2023016477-A9 A CYCLIN-DEPENDENT KINASE INHIBITOR Taizhou Eoc Pharma Co., Ltd. (CN) 2024-04-25 — — WO disclosed
CN-117916235-A Cyclin dependent kinase inhibitors 泰州亿腾景昂药业股份有限公司 2024-04-19 — — CN disclosed
WO-2023016477-A1 A CYCLIN-DEPENDENT KINASE INHIBITOR Taizhou Eoc Pharma Co., Ltd. (CN) 2023-02-16 — — WO disclosed
WO-2023016477-A1 A CYCLIN-DEPENDENT KINASE INHIBITOR Taizhou Eoc Pharma Co., Ltd. (CN) 2023-02-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240343713-A1 TELOMERASE INHIBITOR COMPOUNDS TERT, POT1, TERF2 DPP4 1722/4885SMARCA2 725/4885SMARCA4 523/4885
US-20240352016-A1 A CYCLIN-DEPENDENT KINASE INHIBITOR CDK2, CCNK, CDK1 DPP4 3047/4885SMARCA2 699/4885SMARCA4 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback